Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has completed its previously announced acquisition of a portfolio of five consumer healthcare products from Sanofi (Euronext: SAN; NYSE: SNY). The most significant product is Prontalgine^®, an analgesic for the treatment of moderate to severe pain, only sold in France. The portfolio also includes Buscopan^®, an antispasmodic (sold in the Czech Republic, Estonia, Hungary, Latvia, Poland and Slovakia), Suppositoria Glycerini, a laxative (sold in the Czech Republic), as well as Mucothiol^® and Mucodyne^®, expectorants for cough and flu, sold respectively in Greece and the Republic of Ireland.

This transaction strengthens the evolution of Ipsen Consumer Healthcare portfolio in France and Central Europe with the strategic intent to further develop the OTx¹ model in most geographies